Please ensure Javascript is enabled for purposes of website accessibility

Why Adverum Biotechnologies Stock Is Imploding Today

By Prosper Junior Bakiny - Apr 29, 2021 at 11:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are running for the hills following the company's latest clinical update.

What happened?

Shares of clinical-stage biotech Adverum Biotechnologies (ADVM -1.67%) are plunging on Thursday after the company announced a clinical update regarding one of its pipeline candidates, ADVM-022. Adverum Biotechnologies' stock was down by 60.2% as of 11:30 a.m. EDT. 

So what 

ADVM-022 is an experimental gene therapy for the treatment of diabetic macular edema (DME). After the close of yesterday's trading session, Adverum Biotechnologies announced a suspected adverse reaction in a phase 2 clinical trial evaluating ADVM-022 in DME patients. Specifically, one patient treated with ADVM-022 during the trial developed hypotony, an eye condition that can lead to decreased vision.

At this point it isn't clear whether treatment with ADVM-022 was responsible for the condition. However, out of an abundance of caution, Adverum Biotechnologies has decided to unmask the study and dig into the data to determine whether other patients who participated in the trial may also be at risk of developing hypotony.

Downward-bound graph on a blackboard.

Image source: Getty Images.

CEO Laurent Fischer said: "The safety of every patient who is participating in our clinical studies with our gene therapy is the utmost priority for us at Adverum. We are fully committed to thoroughly assessing this case and ongoing monitoring of this patient and all patients treated with ADVM-022 with our investigators, data monitoring committee (DMC), scientific advisory board, and healthcare authorities."

Now what

Again, it is worth stressing that treatment with ADVM-022 may not be what caused this adverse reaction. But the market does not like uncertainty, and this news certainly adds a whole lot of uncertainty for Adverum Biotechnologies and its shareholders. That explains why investors are offloading shares of this biotech stock today. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adverum Biotechnologies, Inc. Stock Quote
Adverum Biotechnologies, Inc.
ADVM
$1.18 (-1.67%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.